EP Patent

EP4316488A2 — Methods and compositions for treatment of attention deficit disorder

Assigned to Ironshore Pharmaceuticals & Development Inc · Expires 2024-02-07 · 2y expired

What this patent protects

Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be …

USPTO Abstract

Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 3 to 8 hours, followed by an ascending release rate.

Drugs covered by this patent

Patent Metadata

Patent number
EP4316488A2
Jurisdiction
EP
Classification
Expires
2024-02-07
Drug substance claim
No
Drug product claim
No
Assignee
Ironshore Pharmaceuticals & Development Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.